OpenResearchAlpha

Lung · 20 Nov 2026

Effect of Nerandomilast in US Patients with Idiopathic Pulmonary Fibrosis: a Subgroup Analysis of the FIBRONEER-IPF Trial

Justin M. Oldhamh-index 22, Toby M. Maher, Amy L. Olson, Hui Gu, Donald F. Zoz, Ganesh Raghu, Fernando J. Martinezh-index 27

0
Citations
no database records one yet
0
Citations in 2026
so far
27
Leading author's h-index
Fernando J. Martinez, in QAI's scholar index
20
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Purpose In the placebo-controlled FIBRONEER-IPF trial in patients with IPF, nerandomilast reduced decline in forced vital capacity (FVC), with benefits on clinical outcomes and favorable safety and tolerability. We evaluated the effects of nerandomilast in the US patients. Methods Patients were randomized to receive nerandomilast 9 mg bid, nerandomilast 18 mg bid, or placebo, stratified by antifibrotic therapy (nintedanib/pirfenidone versus neither). In the US subgroup, we assessed change in FVC at week 52; time-to-event endpoints over the whole trial; adverse events over the whole trial. Results Of 1177 patients, 196 (16.7%) were from the US. In US patients, adjusted mean (SE) changes in FVC (mL) were − 257.9 (33.6) with placebo, − 152.7 (32.9) with nerandomilast 9 mg bid (difference vs. placebo 105.2 [95% CI 13.0, 197.4]), and − 126.2 (36.9) with nerandomilast 18 mg bid (difference vs. placebo 131.7 [95% CI 33.8, 229.6]. Compared with placebo, the hazard ratios for time to first acute exacerbation of IPF, hospitalization for respiratory cause, or death were 0.91 (95% CI 0.49, 1.67) for nerandomilast 9 mg bid and 0.60 (95% CI 0.30, 1.22) for nerandomilast 18 mg bid. Adverse events led to treatment discontinuation in 17.1%, 12.9% and 10.7% of the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively. Conclusion The effects of nerandomilast 18 mg bid in US patients in the FIBRONEER-IPF trial were consistent with the overall population. Nerandomilast 18 mg bid slowed FVC decline, with numerical reductions in the risk of clinical outcomes, and favorable safety and tolerability.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Fernando J. Martinez has the highest h-index among the authors (27).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (7)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (20)

What it cites, from open citation data, with Crossref's record of each.